{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:36:04Z","timestamp":1785353764354,"version":"3.55.0"},"reference-count":154,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Although rare bone diseases (RBDs) present mobility challenges, there is little consolidated evidence on evaluated mobility measurement tools or how mobility impairments impact daily activities and quality of life (QoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives and design:<\/jats:title>\n                    <jats:p>This systematic literature review investigated: (1) the impacts of mobility impairment on daily activities\/QoL; (2) the suitability\/comprehensiveness of tools measuring mobility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>MEDLINE\/Embase databases (January 19, 2022) and Google (October 19, 2022) were searched for articles published between 2011 and 2022; conference proceedings from 2020 to 2021 were hand-searched. Included articles reported on how mobility impairments impact daily activities\/QoL, or the use of tools for measuring mobility, in RBDs. A narrative analysis using descriptive statistics was conducted. Studies were assessed for risk of bias using The Alberta Heritage Foundation for Medical Research Quality Assessment Criteria and National Institute of Health Quality Assessment Tool for Case Series Studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Inclusion criteria were met by 113 articles, investigating 39 RBDs (sample sizes:\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20091\u2013959). Mobility impairments, commonly joint function\/gait disturbances, negatively impacted daily activities (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200947 cohorts; frequently walking (27\/47; 57.4%)) and QoL (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200936 cohorts; commonly pain (30\/36; 83.3%; Objective 1). There were 34 functional assessments, 22 questionnaires, and 5 technologies described. Only nine functional assessments\/questionnaires were reported to have good validity\/reliability\/responsiveness for an RBD (not reported for technologies); none comprehensively captured daily living\/QoL impacts of mobility impairment. The quality of studies was moderate, though many were case studies\/series, which are at inherent risk of bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Few tools comprehensively captured mobility impairments and associated impacts on daily activities\/QoL. Consistent reporting of tools\u2019 validity\/reliability\/responsiveness would support clinicians in selecting methods for use across RBD populations. Used remotely, wearables could support understanding of real-world mobility challenges. Since searches were conducted, additional technologies (e.g., remote gait analysis) have been tested in RBDs, although validation is required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol PROSPERO registration:<\/jats:title>\n                    <jats:p>CRD42022311513. Sponsored by Ipsen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x251369963","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T07:09:35Z","timestamp":1755760175000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["A systematic literature review of the impact and measurement of mobility impairment in rare bone diseases"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8963-4736","authenticated-orcid":false,"given":"In\u00eas","family":"Alves","sequence":"first","affiliation":[{"name":"School of Health and Human Development, Comprehensive Health Research Centre, University of \u00c9vora, Largo dos Colegiais 2, \u00c9vora 7004-516, Portugal"},{"name":"National Association of Skeletal Dysplasia (ANDO Portugal), \u00c9vora, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"Westerheim","sequence":"additional","affiliation":[{"name":"Osteogenesis Imperfecta Federation Europe, Heffen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-106X","authenticated-orcid":false,"given":"Edward C.","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, The UCSF Metabolic Bone Clinic, The Eli and Edythe Broad Institute for Regeneration Medicine, The Institute of Human Genetics, Department of Medicine, The UCSF Program in Craniofacial Biology, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaymin","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA, USA"},{"name":"Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sangiorgi","sequence":"additional","affiliation":[{"name":"Department of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Artyomenko","sequence":"additional","affiliation":[{"name":"Ipsen, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Croskery","sequence":"additional","affiliation":[{"name":"Ipsen, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4361-2837","authenticated-orcid":false,"given":"Juliet","family":"Johns","sequence":"additional","affiliation":[{"name":"Costello Medical, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6183-4143","authenticated-orcid":false,"given":"Emma","family":"Warnants","sequence":"additional","affiliation":[{"name":"Costello Medical, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Barton","sequence":"additional","affiliation":[{"name":"Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02506-3"},{"key":"e_1_3_5_3_2","unstructured":"ERN Bond. Rare bone diseases https:\/\/ernbond.eu\/bone-rare-diseases\/ (2025 accessed 14 July 2025)."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61366"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.63132"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","unstructured":"Eileen MS Maurizio P. JBMRPlus: Special issue on rare bone diseases. JBMR Plus 2019; 3: e10218. https:\/\/doi.org\/10.1002\/jbm4.10218","DOI":"10.1002\/jbm4.10218"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02611-3"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2021.101392"},{"key":"e_1_3_5_9_2","volume-title":"Voice of the patient report","author":"Faitos S","unstructured":"Faitos S, Inman J, Jones G, et al. Voice of the patient report. Paper presented at the Symposium on Hypophosphatemia: Past, Present, and Future, 23 July 2019, Baltimore, MD."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05548-0"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2115360"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001714"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0491-4"},{"key":"e_1_3_5_14_2","volume-title":"Addressing a knowledge gap: characterizing the physical, functional, and cognitive performance in adults with hypophosphatasia","author":"Dourrough C","unstructured":"Dourrough C, Dahir K. Addressing a knowledge gap: characterizing the physical, functional, and cognitive performance in adults with hypophosphatasia. Paper presented at the 2020 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), Virtual Event, September 11\u201315, 2020, pp. S1\u2013S349."},{"key":"e_1_3_5_15_2","first-page":"148","article-title":"Perceived mobility challenges in rare bone diseases: how real-world gait data aligns","volume":"2","author":"Fink S","year":"2024","unstructured":"Fink S, Suppanz M, Castro M, et al. Perceived mobility challenges in rare bone diseases: how real-world gait data aligns. J Orth Clin Res 2024; 2: 148\u2013161.","journal-title":"J Orth Clin Res"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2024.05.033"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-94212-0_5"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-021-00336-8"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03126-9"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-014-2892-z"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1004-x"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/09638288.2017.1405083"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115964"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac120"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4690-7"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_3_5_28_2","volume-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","author":"Centre for Reviews and Dissemination, University of York","year":"2008","unstructured":"Centre for Reviews and Dissemination, University of York. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. University of York: Centre for Reviews and Dissemination, 2008."},{"key":"e_1_3_5_29_2","volume-title":"Standard quality assessment criteria for evaluating primary research papers from a variety of fields","author":"Kmet LM","year":"2004","unstructured":"Kmet LM, Cook LS, Lee R. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta Heritage Foundation for Medical Research (AHFMR), 2004."},{"key":"e_1_3_5_30_2","unstructured":"National Institutes of Health. Study quality assessment tools https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools (2025 accessed 14 August 2025)."},{"key":"e_1_3_5_31_2","first-page":"228","article-title":"Multiple skeletal deformities in a middle-aged man","volume":"34","author":"Mart\u00ednez-M\u00e9ndez JH","year":"2015","unstructured":"Mart\u00ednez-M\u00e9ndez JH, Guti\u00e9rrez-Acevedo MG-C, Mangual-Garc\u00eda AA, et al. Multiple skeletal deformities in a middle-aged man. P R Health Sci J 2015; 34: 228\u2013230.","journal-title":"P R Health Sci J"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-32"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4130"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.01.013"},{"key":"e_1_3_5_35_2","first-page":"1","article-title":"Health related quality of life, disability, and pain in alpha mannosidosis: long-term data of enzyme replacement therapy with velmanase alfa (human recombinant alpha mannosidase)","volume":"6","author":"Borgwardt L","year":"2018","unstructured":"Borgwardt L, Guffon N, Amraoui Y, et al. Health related quality of life, disability, and pain in alpha mannosidosis: long-term data of enzyme replacement therapy with velmanase alfa (human recombinant alpha mannosidase). J Inborn Errors Metab 2018; 6: 1\u201312.","journal-title":"J Inborn Errors Metab"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00275"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.3233\/PRM-170523"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20285"},{"key":"e_1_3_5_39_2","article-title":"P673: patient-reported outcomes of X-linked hypophosphataemia registry participants in the UK","author":"Cole S","year":"2020","unstructured":"Cole S, Sanchez-Santos MT, Barrett J, et al. P673: patient-reported outcomes of X-linked hypophosphataemia registry participants in the UK. In: World congress of osteoporosis, osteoarthritis and musculoskeletal diseases (WCO-IOF-ESCEO), virtual event, 2020.","journal-title":"World congress of osteoporosis, osteoarthritis and musculoskeletal diseases (WCO-IOF-ESCEO)"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0538-4"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2021.01091"},{"key":"e_1_3_5_42_2","first-page":"333","article-title":"Hypophosphatemia linked to chromosome X (XLH): impact on the quality of life","volume":"30","author":"Monzo JJB","year":"2019","unstructured":"Monzo JJB, Romero LCL, Guillen E, et al. Hypophosphatemia linked to chromosome X (XLH): impact on the quality of life. J Am Soc Nephrol 2019; 30: 333.","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_5_43_2","volume-title":"P2-284: associations between height and health-related quality of life (HRQoL) and functional independent in children with achondroplasia","author":"Irving M","year":"2021","unstructured":"Irving M, Savarirayan R, Arundel P, et al. P2-284: associations between height and health-related quality of life (HRQoL) and functional independent in children with achondroplasia. Paper presented at the Annual Meeting of the European Society of Paediatric Endocrinology (ESPE), virtual event, 2021."},{"key":"e_1_3_5_44_2","article-title":"Applying the functional independence measure to the assessment of patients with mucopolysaccharidosis","volume":"51","author":"Matos MA","year":"2020","unstructured":"Matos MA, Silva Lopes P, Rodrigues Corsini A, et al. Applying the functional independence measure to the assessment of patients with mucopolysaccharidosis. Colomb Med (Cali) 2020; 51: e213996.","journal-title":"Colomb Med (Cali)"},{"key":"e_1_3_5_45_2","doi-asserted-by":"crossref","unstructured":"Al Mukaddam M Toder KS Davis M et al. Assessment of the impact of fibrodysplasia ossificans progressiva on quality of life for patients and their families using an international burden of illness survey. In: International Society for Pharmacoeconomics and Outcomes (ISPOR)\u2014Europe virtual event 2021 p. POSA426.","DOI":"10.1016\/j.jval.2021.11.1328"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1068-7"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115274"},{"key":"e_1_3_5_48_2","volume-title":"P-847: validity and reliability of the Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ), a patient-reported, disease-specific measure","author":"Pignolo RJ","year":"2020","unstructured":"Pignolo RJ, Kimel M, Whalen J, et al. P-847: validity and reliability of the Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ), a patient-reported, disease-specific measure. Paper presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting virtual event, 2020."},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1167-5"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.07.006"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01857-7"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-03835-9"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10395"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2021.106213"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2021.03.011"},{"key":"e_1_3_5_56_2","article-title":"FRI-893: Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia","author":"Seefried L","unstructured":"Seefried L, Rak D, Genest F, et al. FRI-893: Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia. Paper presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting, 2019, Orlando, FL.","journal-title":"Paper presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting, 2019, Orlando, FL"},{"key":"e_1_3_5_57_2","first-page":"53","article-title":"Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population","volume":"49","author":"Haller C","year":"2019","unstructured":"Haller C, Song W, Cimms T, et al. Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population. JIMD Rep 2019; 49: 53\u201362.","journal-title":"JIMD Rep"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01545-y"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0636"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000000513"},{"key":"e_1_3_5_61_2","volume-title":"7th International conference on children\u2019s bone health","author":"Phillips D","year":"2015","unstructured":"Phillips D, Griffin D, Przybylski T, et al. P136: a modified performance-oriented mobility assessment tool for assessing clinically relevant gait impairments and change in children with hypophosphatasia: development and validation. In: 7th International conference on children\u2019s bone health, 2015, Salzburg, Austria."},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00365"},{"key":"e_1_3_5_63_2","article-title":"Impaired mobility and pain significantly impact the quality of life of children with X-linked hypophosphatemia","volume":"4","author":"Linglart A","year":"2015","unstructured":"Linglart A, Dvorak-Ewell M, Marshall A, et al. Impaired mobility and pain significantly impact the quality of life of children with X-linked hypophosphatemia. Bone Abstracts 2015; 4: P198.","journal-title":"Bone Abstracts"},{"key":"e_1_3_5_64_2","article-title":"POSA426: assessment of the economic impact of fibrodysplasia ossificans progressiva on patients and their families using an international burden of illness survey","volume":"25","author":"Al Mukaddam M","year":"2022","unstructured":"Al Mukaddam M, Toder KS, Davis M, et al. POSA426: assessment of the economic impact of fibrodysplasia ossificans progressiva on patients and their families using an international burden of illness survey. Value Health 2022; 25: S273.","journal-title":"Value Health"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.06.005"},{"key":"e_1_3_5_66_2","volume-title":"P790: X-linked hypophosphataemic rickets: description of 16 cases in the adulthood in Argentina","author":"Martinez T","year":"2020","unstructured":"Martinez T, Schiro LM, Rodriguez P, et al. P790: X-linked hypophosphataemic rickets: description of 16 cases in the adulthood in Argentina. Paper presented at the American Society for Bone and Mineral Research Annual Meeting (ASBMR), virtual event, 2020."},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.2482"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a006134"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0362-2"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.536"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475"},{"key":"e_1_3_5_72_2","volume-title":"Efficacy of burosumab in older adults with X-linked hypophosphataemia (XLH): a subgroup analysis of a randomized, double-blind, placebo controlled, phase 3 study. P-755","author":"Keen R","year":"2020","unstructured":"Keen R, Insogna K, Sun W, et al. Efficacy of burosumab in older adults with X-linked hypophosphataemia (XLH): a subgroup analysis of a randomized, double-blind, placebo controlled, phase 3 study. P-755. Paper presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting, virtual event, 2020."},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-6-196"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.1301"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00568-3"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2016.05.004"},{"key":"e_1_3_5_77_2","article-title":"PRO152 Confirmatory psychometric validation of the Western Ontario Mcmaster Universities Osteoarthritis Inventory (WOMAC) in adult X-linked hypophosphatemia (XLH)","volume":"22","author":"Skrinar A","year":"2019","unstructured":"Skrinar A, Theodore-Oklota C, Bonner N, et al. PRO152 Confirmatory psychometric validation of the Western Ontario Mcmaster Universities Osteoarthritis Inventory (WOMAC) in adult X-linked hypophosphatemia (XLH). Value Health 2019; 22: S870.","journal-title":"Value Health"},{"key":"e_1_3_5_78_2","article-title":"PRO154 Confirmatory psychometric validation of the Brief Pain Inventory (BPI-SF) in adult X-linked hypophosphatemia (XLH)","volume":"22","author":"Skrinar A","year":"2019","unstructured":"Skrinar A, Theodore-Oklota C, Bonner N, et al. PRO154 Confirmatory psychometric validation of the Brief Pain Inventory (BPI-SF) in adult X-linked hypophosphatemia (XLH). Value Health 2019; 22: S870.","journal-title":"Value Health"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.artd.2021.02.018"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01682-y"},{"key":"e_1_3_5_81_2","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfecta\u2014a first prospective trial","volume":"16","author":"Hoyer-Kuhn H","year":"2016","unstructured":"Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfecta\u2014a first prospective trial. J Musculoskelet Neuronal Interact 2016; 16: 24\u201332.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2020.07.090"},{"key":"e_1_3_5_83_2","first-page":"219","article-title":"Hypophosphatasia treatment with recombinant human TNSALP in an 18\u2009year old patient","volume":"129","author":"Belaya Z","year":"2019","unstructured":"Belaya Z, Kalinchenko N, Grebennikova T, et al. Hypophosphatasia treatment with recombinant human TNSALP in an 18\u2009year old patient. J Bone Miner Res 2019; 129: 219\u2013227.","journal-title":"J Bone Miner Res"},{"key":"e_1_3_5_84_2","first-page":"365","article-title":"Impact of early diagnosis and treatment with enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study. E-139","volume":"42","author":"Ficicioglu C","year":"2019","unstructured":"Ficicioglu C, Benedict M, Kornafel T. Impact of early diagnosis and treatment with enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study. E-139. J Inherit Metab Dis 2019; 42: 365\u2013366.","journal-title":"J Inherit Metab Dis"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01618-y"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.02.006"},{"key":"e_1_3_5_87_2","article-title":"Eccentric training as an adjunct to rehabilitation program for hereditary multiple exostoses: a case report","volume":"10","author":"Kanik ZH","year":"2016","unstructured":"Kanik ZH, Gunaydin G, Sozlu U, et al. Eccentric training as an adjunct to rehabilitation program for hereditary multiple exostoses: a case report. J Clin Diagn Res 2016; 10: YD03\u2013YD04.","journal-title":"J Clin Diagn Res"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61464"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-21"},{"key":"e_1_3_5_90_2","article-title":"X-linked hypophosphatemia patient work-up at St. Vincent\u2019s University Hospital is managed to European consensus guidelines","volume":"190","author":"McDermott M","year":"2021","unstructured":"McDermott M, Twomey P, Van der Kamp S, et al. X-linked hypophosphatemia patient work-up at St. Vincent\u2019s University Hospital is managed to European consensus guidelines. Ir J Med Sci 2021; 190: S94\u2013S95.","journal-title":"Ir J Med Sci"},{"key":"e_1_3_5_91_2","first-page":"100643","article-title":"Marked motor function improvement in a 32-year-old woman with childhood-onset hypophosphatasia by asfotase alfa therapy: evaluation based on standardized testing batteries used in Duchenne muscular dystrophy clinical trials","volume":"25","author":"Nishizawa H","year":"2020","unstructured":"Nishizawa H, Sato Y, Ishikawa M, et al. Marked motor function improvement in a 32-year-old woman with childhood-onset hypophosphatasia by asfotase alfa therapy: evaluation based on standardized testing batteries used in Duchenne muscular dystrophy clinical trials. Mol Genet Metab Rep 2020; 25: 100643.","journal-title":"Mol Genet Metab Rep"},{"key":"e_1_3_5_92_2","article-title":"Gait assessment in children with childhood hypophosphatasia: impairments in muscle strength and physical function","volume":"4","author":"Phillips D","year":"2015","unstructured":"Phillips D, Griffin D, Przybylski T, et al. Gait assessment in children with childhood hypophosphatasia: impairments in muscle strength and physical function. Bone Abstracts 2015; 4: P103.","journal-title":"Bone Abstracts"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1371"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jht.2021.03.003"},{"key":"e_1_3_5_95_2","first-page":"445","article-title":"A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta","volume":"14","author":"Hoyer-Kuhn H","year":"2014","unstructured":"Hoyer-Kuhn H, Semler O, Stark C, et al. A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact 2014; 14: 445\u2013453.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"e_1_3_5_96_2","first-page":"653","article-title":"Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta","volume":"24","author":"Atta I","year":"2014","unstructured":"Atta I, Iqbal F, Lone SW, et al. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta. J Coll Physicians Surg Pak 2014; 24: 653\u2013657.","journal-title":"J Coll Physicians Surg Pak"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2020.01.003"},{"key":"e_1_3_5_98_2","doi-asserted-by":"crossref","unstructured":"Al Mukaddam M Pignolo RJ Baujat G et al. AEP1019: a global natural history study of Fibrodysplasia Ossificans Progressiva (FOP): 12-month outcomes. Endocr Abstr 2020; 70: AEP1019.","DOI":"10.1530\/endoabs.70.AEP1019"},{"key":"e_1_3_5_99_2","article-title":"A natural history study of fibrodysplasia ossificans progressiva (FOP): 12-month outcome results","volume":"13","author":"Pignolo RJ","year":"2020","unstructured":"Pignolo RJ, Baujat G, Brown MA, et al. A natural history study of fibrodysplasia ossificans progressiva (FOP): 12-month outcome results. Bone Rep 2020; 13: P325.","journal-title":"Bone Rep"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2022.07.261"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otsr.2017.11.014"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015908"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1197-z"},{"key":"e_1_3_5_104_2","first-page":"85","article-title":"Rubinstein-Taybi syndrome: a rare case report of a female child emphasizing physiotherapy on gross motor function","volume":"40","author":"Kovela RK","year":"2021","unstructured":"Kovela RK, Qureshi MI, Manakandathil AS, et al. Rubinstein-Taybi syndrome: a rare case report of a female child emphasizing physiotherapy on gross motor function. Pan Afr Med J 2021; 40: 85.","journal-title":"Pan Afr Med J"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.4103\/jcvjs.JCVJS_164_20"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1097\/PEP.0000000000000176"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-12-32"},{"key":"e_1_3_5_108_2","volume-title":"Presented at the American Society for Bone and Mineral Research Annual Meeting (ASBMR), virtual event","author":"Carpenter T","year":"2020","unstructured":"Carpenter T, Tabatabai L, Luca D, et al. P-788: safety and efficacy of burosumab in cutaneous skeletal hypophosphatemia syndrome (CSHS). Presented at the American Society for Bone and Mineral Research Annual Meeting (ASBMR), virtual event, 2020."},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115795"},{"key":"e_1_3_5_110_2","article-title":"Physical function and mobility in adults with X-linked hypophosphatemia","volume":"31","author":"Orlando G","year":"2020","unstructured":"Orlando G, Clark S, Javaid MK, et al. Physical function and mobility in adults with X-linked hypophosphatemia. Osteoporos Int 2020; 31: S345.","journal-title":"Osteoporos Int"},{"key":"e_1_3_5_111_2","volume-title":"P191: physical function and mobility in adults with X-linked hypophosphatemiavirtual event","author":"Orlando G","year":"2021","unstructured":"Orlando G, Clarke S, Roy M, et al. P191: physical function and mobility in adults with X-linked hypophosphatemia. Paper presented at the 48th European Calcified Tissue Society Congress, virtual event, 2021."},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.CC.N.00177"},{"key":"e_1_3_5_113_2","first-page":"1","article-title":"Sarcopenia and its association with objectively measured life-space mobility and moderate-to-vigorous physical activity in the oldest-old amid the COVID-19 pandemic when a physical distancing policy is in force","volume":"22","author":"Yiu Cho Kwan R","year":"2022","unstructured":"Yiu Cho Kwan R, Yat Wa Liu J, Yin Y, et al. Sarcopenia and its association with objectively measured life-space mobility and moderate-to-vigorous physical activity in the oldest-old amid the COVID-19 pandemic when a physical distancing policy is in force. BMC Geriatr 2022; 22: 1\u201311.","journal-title":"BMC Geriatr"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.754084"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01427-3"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.jfas.2012.05.008"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10216"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1062-0"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0629-x"},{"key":"e_1_3_5_120_2","volume-title":"International classification of functioning, disability and health","author":"World Health Organisation (WHO)","year":"2001","unstructured":"World Health Organisation (WHO). International classification of functioning, disability and health, Geneva: World Health Organization, 2001."},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000616"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jht.2018.05.001"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.02.009"},{"key":"e_1_3_5_124_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622317739538"},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36545"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac518"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12081205"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1138599"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03168-w"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03678-4"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03048-6"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03694-4"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175174"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2025.02.001"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00493-w"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-6-201303190-00003"},{"key":"e_1_3_5_137_2","unstructured":"Verlinden JM. How much does it cost to build a Health Tech Application? Med Record https:\/\/medrecord.io\/cost-of-developing-healthtech-apps\/ (accessed 2023 14 August 2025)."},{"key":"e_1_3_5_138_2","unstructured":"APA Member Services. Using apps in clinical practice: competency considerations. American Psychological Association https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fwww.apa.org%2Fmembers%2Fcontent%2Fclinical-practice-apps-transcript.docx&wdOrigin=BROWSELINK (2019 accessed July 2025)."},{"key":"e_1_3_5_139_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269615"},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2023.05.029"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.1159\/000517411"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.2196\/50035"},{"key":"e_1_3_5_143_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02388-5"},{"key":"e_1_3_5_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2024.104977"},{"key":"e_1_3_5_145_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000104"},{"key":"e_1_3_5_146_2","doi-asserted-by":"publisher","DOI":"10.2196\/26004"},{"key":"e_1_3_5_147_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0305-8"},{"key":"e_1_3_5_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117034"},{"key":"e_1_3_5_149_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25610-7"},{"key":"e_1_3_5_150_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1111104"},{"key":"e_1_3_5_151_2","unstructured":"National Institute of Neurological Disorders and Stroke. Motor neuron diseases https:\/\/www.ninds.nih.gov\/health-information\/disorders\/motor-neuron-diseases (2025 accessed 14 August 2025)."},{"key":"e_1_3_5_152_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad589"},{"key":"e_1_3_5_153_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00794"},{"key":"e_1_3_5_154_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020625"},{"key":"e_1_3_5_155_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036367"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X251369963","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X251369963","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X251369963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:40:12Z","timestamp":1777588812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X251369963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":154,"alternative-id":["10.1177\/1759720X251369963"],"URL":"https:\/\/doi.org\/10.1177\/1759720x251369963","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"1759720X251369963"}}